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he transmembrane ligand ephrinB2 and its receptor tyrosine kinase EphB4 are molecular markers of embryonic arterial
nd venous endothelial cells, respectively, and are essential for angiogenesis. Here we show that expression of ephrinB2
ersists in adult arteries where it extends into some of the smallest diameter microvessels, challenging the classical view
hat capillaries have neither arterial nor venous identity. EphrinB2 also identifies arterial microvessels in several settings
f adult neovascularization, including tumor angiogenesis, contravening the dogma that tumor vessels arise exclusively
rom postcapillary venules. Unexpectedly, expression of ephrinB2 also defines a stable genetic difference between arterial
nd venous vascular smooth muscle cells. These observations argue for revisions of classical concepts of capillary identity
nd the topography of neovascularization. They also imply that ephrinB2 may be functionally important in neovascular-
zation and in arterial smooth muscle, as well as in embryonic angiogenesis. © 2001 Academic Pressn
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The vertebrate circulatory system comprises arteries
and veins, defined by the direction of blood flow. Re-
cently, we discovered serendipitously that arterial and
venous endothelial cells (ECs) are genetically distinct,
from the earliest stages of angiogenesis (Wang et al.,
1998). EphrinB2, a transmembrane ligand (Bennett et al.,
1995; Bergemann et al., 1995), is expressed by arteries but
1 These two authors contributed equally to this work.
2 To whom correspondence should be addressed. Fax: (626)64-8243.
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All rights of reproduction in any form reserved.ot veins, whereas one of its receptors, the tyrosine
inase EphB4, is more abundantly expressed by veins
han by arteries (Wang et al., 1998).
The genes ephrinB2 and EphB4 are also essential for
roper development of the cardiovascular system. Tar-
eted null mutations in these genes cause embryonic
ethality by E10.0, accompanied by defects in angiogenic
emodeling of the peripheral vasculature and defective
yocardial trabeculation in the heart (Adams et al., 1999;
Gerety et al., 1999; Wang et al., 1998). As EphB4 is
known to interact only with ephrinB2 among all ephrinB-
class ligands (Bergemann et al., 1998; Brambilla et al.,
1996; Brambilla et al., 1995; Sakano et al., 1996), the
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140 Shin et al.symmetrical mutant phenotypes of this ligand–receptor
pair suggest that their interaction is essential for cardio-
vascular development. Furthermore, since ephrinB-class
transmembrane ligands are capable of signal transduction
upon engagement of EphB-class receptors (Bruckner et
al., 1997; Holland et al., 1996), these genetic data are
onsistent with the idea that ephrinB2 and EphB4 medi-
te bidirectional signaling (Mellitzer et al., 1999; Xu et
FIG. 1. Specific expression of ephrinB2 in arteries but not veins o
E), spleen (D), intestinal fat (F), leg muscle (G), and brain (H). (A–D)
staining; (H) X-Gal staining alone. Arrowheads indicate ephrinB21l., 1999). m
Copyright © 2001 by Academic Press. All rightOne outstanding question raised by our previous studies
s whether the arterial-specific expression of ephrinB2 per-
ists into adulthood, in either stable and/or newly forming
lood vessels. This question is important for two reasons.
irst, it was not clear whether the identity distinctions
etween arteries and veins required to assemble the circu-
atory system necessarily need to be maintained once
evelopment is complete. Second, the essential require-
lt organs. The tissues illustrated are kidney (A), heart (B), liver (C,
al and hematoxylin staining; (E–G), X-Gal and PECAM-1 antibody
ries; arrows indicate ephrinB22 veins.f adu
, X-Gent of ephrinB2 for embryonic angiogenesis raised the
s of reproduction in any form reserved.
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141Arterial-Specific Expression of EphrinB2 in AdultsFIG. 2. Comparison of ephrinB2 and Eph-B4 expression between dorsal aorta and vena cava of adults. EphrinB2 expression in dorsal aorta
A, C) and vena cava (B, D) was detected by X-Gal staining for 3 h (A, B), and by double-label immunofluorescence confocal microscopy (C,
) with antibodies to PECAM-1 (green) and b-galactosidase (red). Arrows in (B, D) indicate longitudinal stripes of ephrinB2 expression in
Copyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
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142 Shin et al.possibility that it might be functionally important in set-
tings of adult neovascularization, like other signaling mol-
ecules involved in angiogenesis (Lin et al., 1998). The data
presented here indeed suggest a role for ephrinB2 in neovas-
cularization of arteries and uncover an unexpected poten-
tial role for the ligand in arterial smooth muscle cells as
well.
MATERIALS AND METHODS
Corneal Micropocket Assay, Bromodeoxyuridine
(Brdu) Labeling, and Wound Healing Model
Corneal pockets were made as described (Kenyon et al., 1996)
nd implanted with pellets containing 200 ng of VEGF at 1.0 mm
rom the corneal limbus. BrdU was delivered at a rate of 26 mg per
our for 7 days, by a subcutaneous osmotic pump (Alzet) implanted
mmediately after corneal micropocket surgery. Full-thickness
kin wounds were made using a sterile, disposable 4-mm punch
iopsy (Baker Cummins Dermatological) and were examined 7 days
fterward.
Tumor Models
Lewis lung carcinomas or B16F10 melanomas were grown in the
dorsal subcutaneous space of adult female ephrinB2taulacZ/1 mice as
reviously described (O’Reilly et al., 1997). Mice bearing 200-mm3
tumors were anesthetized and sacrificed, and tumors were embed-
ded in OCT, sectioned at 20 mm, and double-stained with X-Gal
and anti-PECAM immunoperoxidase histochemistry. Procedural
details are available on request.
Histochemical and Immunocytochemical Analysis
Animals were anesthetized and perfused with 0.1 M Pipes (pH
7.0) followed by 2% paraformaldehyde (PFA)/0.1 M Pipes. Vessel
segments were excised and placed in 0.2% PFA/Pipes overnight at
4°C, rinsed, and stained for 3.5 h in X-Gal buffer. LacZ-stained
vessels were embedded in OCT, sectioned at 10 mm, air-dried, and
postfixed in 2% PFA/PBS. Organs were excised, embedded in OCT,
and sectioned at 20 mm. Sections were stained in X-Gal buffer for
6 h to overnight at 30°C and postfixed in 2% PFA/PBS for 5 min.
Antibody staining of cutaneous wound and corneal tissues was
performed as described (Gerety et al., 1999; Wang et al., 1998), on
nstained or X-Gal-stained cryostat sections, using the following
the vein; arrowheads indicate individual ephrinB21 endothelial cel
etected by X-Gal staining (E, F) for 3 h, by Nickel-DAB-enhanced
and by confocal microscopy (I, J) with anti-PECAM-1 (green) and
ndividual EphB41 cells can be detected in the artery by X-Gal histo
appears much lower than that in veins when detected by anti-bgal
han is the histochemical reaction. Note the characteristic wavy de
D, J), which may reflect differences in blood flow rates and/or she
the narrow peaks of the waves (E, I, arrows) although a few are seen
in (C) vs (I) or (D) vs (J) are not directly comparable.
Copyright © 2001 by Academic Press. All rightrimary antibodies: anti-mouse PECAM-1 (clone MEC 13.3,
harmingen), anti-b gal (5-prime, 3-prime), anti-Brdu (Accurate),
and Cy3-conjugated anti-SMA (Sigma).
RESULTS
ephrinB2 Is Expressed in Adult Arteries,
Microvessels, and Capillaries
We examined the expression of ephrinB2 using a taul-
acZ reporter (Lundgren et al., 1995; Mombaerts et al.,
1996) targeted to the ephrinB2 locus (Wang et al., 1998),
which provides a histochemical indicator of ephrinB2
transcription. A comparison of ephrinB2taulacZ expression
ith that of authentic ephrinB2 mRNA previously indi-
ated that the taulacZ reporter faithfully reproduces the
expression pattern of the endogenous gene in embryos
(Bergemann et al., 1995; Sakano et al., 1996; Wang and
Anderson, 1997; Wang et al., 1998). Similar ephrinB2
reporter mice have been independently generated by
others and show essentially the same expression pattern
(Adams et al., 1999; see Gale et al., 2001). The viability
and fertility of adult ephrinB2taulacZ/1 heterozygous “indi-
ator” mice allowed us to examine the expression of the
aulacZ marker gene in the vasculature of adult animals.
Sections through various adult organs of
phrinB2taulacZ/1 mice revealed expression in arteries of
varied diameters (Fig. 1, arrowheads), but not veins (Fig.
1, arrows). These tissues included the kidney (Fig. 1A),
heart (Fig. 1B), liver (Fig. 1C, E), spleen (Fig. 1D), fat (Fig.
1F), muscle (Fig. 1G), and brain (Fig. 1H). In some
sections, there appeared to be a patchy, low-level expres-
sion of the reporter in veins. To examine this more
clearly, we stained the dorsal aorta and vena cava of
indicator mice in whole mount and opened the vessels to
visualize the luminal surface en face (Fig. 2). With X-Gal
reaction times (3 h) that completely saturated the stain-
ing in the dorsal aorta (Fig. 2A), patchy staining was
visible in the vena cava (Fig. 2B). This staining had two
characteristic morphologies: narrow longitudinal stripes
(Fig. 2B, arrow), and smaller patches (Fig. 2B, arrowhead).
Double-label confocal immunofluorescence microscopy
with antibodies to b-galactosidase (Fig. 2D, red) and the
an-endothelial marker PECAM-1 (Fig. 2D, green) re-
h-B4 expression in dorsal aorta (E, G, I) and vena cava (F, H, J) was
unoperoxidase staining with anti-b-galactosidase antibody (G, H)
l (red) antibodies. All pictures were taken with a 40X objective.
ical staining (E, arrow and arrowhead), but the level of expression
ody staining (G vs H), which is more proportional to protein levels
ation of the intimal surface of the artery (C, I) compared to the vein
ces. Most of the EphB41 cells in the artery appear associated with
e broader “troughs” (E, arrowhead). The levels of b-gal expressionls. Ep
imm
b-ga
chem
antib
form
ar for
in ths of reproduction in any form reserved.
d
o
s
l
a
2
e
s
l
w
w
3
g
a
E
s
t
e
e
S
t
D
s
s
e
t
1
e
b
s
m
s
r
m
b
5
c
D
i
c
m
o
c
t
c
v
f
l
t
143Arterial-Specific Expression of EphrinB2 in Adultsvealed that the patches of weak b-galactosidase expres-
sion occurred in endothelial cells (Fig. 2D, arrowheads),
while the longitudinal stripes did not (Fig. 2D, arrows). It
is possible that these longitudinal stripes represent
smooth muscle cells (see below) in the vaso vasorum, the
small vessels of arterial origin that supply blood to the
walls of large veins, or neural structures surrounding the
vessel wall. Interestingly, the en face visualization re-
vealed a characteristic wavy pattern of endothelial cells
in the aorta (Figs. 2C, I) that was not seen in the vena cava
(Figs. 2D, J). This difference in the distortion of the
intimal surface may reflect differences in the ambient
conditions of the two vessel types at the time of fixation.
The recent availability of EphB4taulacZ/1 indicator mice
(Gerety et al., 1999) permitted us to determine whether the
preferential expression of EphB4 in veins persists into
adulthood as well. Expression of EphB4 was clearly detected
in adult veins such as the vena cava (Fig. 2F and data not
shown). However EphB4 expression in the vena cava was
not uniform, but rather distributed in islands of contiguous
endothelial cells (Figs. 2F, H, J), revealing an apparent
cellular heterogeneity in the composition of the venous
endothelial wall. Individual EphB41 cells could also be
etected in the dorsal aorta (Fig. 2E, arrow), as well as in
ther arteries (data not shown). The level of EphB4 expres-
ion in these scattered arterial endothelial cells was clearly
ower than that in veins, however, when detected by
nti-b-galactosidase antibody staining (Fig. 2G vs Figs. 2H,
I vs Fig. 2J).
Expression of ephrinB2 in the adult vasculature was
vident not only in major vessels, but persisted into the
mallest diameter microvessels and capillaries. Double-
abeling with antibody to PECAM-1 revealed that ephrinB2
as expressed in a subset of these microvessels (Fig. 3). This
as evident in multiple tissues, including pancreas (Fig.
A), muscle (Figs. 3B, J–L), intestinal fat (Fig. 3C), kidney
lomeruli (Figs. 3D–F) and brain, liver, adrenal cortex, and
drenal medulla (data not shown). Similarly, expression of
phB4taulacZ extended from larger diameter veins into a
ubset of microvessels and capillaries in the glomerulus of
he kidney (Figs. 3G–I) and muscle (Figs. 3M–O).
ephrinB2 Is Expressed in Vascular Smooth Muscle
of Arteries but Not Veins
In the course of examining the expression of the
ephrinB2taulacZ indicator gene in arteries we noted that
xpression of the marker appeared to extend from the
ndothelial into the smooth muscle layer (Figs. 4A–D).
uch smooth muscle expression of ephrinB2 was not de-
ected in the veins examined in this study (Fig. 4D, VC).
ouble-labeling with antibodies to b-galactosidase (Fig. 4F,
red) and alpha smooth muscle actin (SMA) (Fig. 4F, green)
confirmed that ephrinB2 is expressed in smooth muscle
cells in the arterial walls (Fig. 4F, yellow patches), although
not all of the smooth muscle cells were ephrinB21. Because c
Copyright © 2001 by Academic Press. All rightof the close apposition of endothelial and smooth muscle
cells in these adult vessels and diffusion of the X-Gal
reaction product, it was difficult to determine whether
ephrinB2 expression was in fact maintained in arterial
endothelial cells (Figs. 4A–D, arrows). This was confirmed,
however, by double-label immunofluorescence with anti-
bodies to b-galactosidase and PECAM-1 (Fig. 4E, yellow
taining).
The observation of ephrinB2 expression in adult arterial
mooth muscle cells was surprising, as initial studies of its
xpression in embryonic arteries had failed to detect it in
he smooth muscle layer (Adams et al., 1999; Wang et al.,
998). However, these studies were performed in very early
mbryos (E9.5–E10.5), raising the possibility that ephrinB2
ecame expressed in arterial smooth muscle cells at later
tages of development not previously examined. In confir-
ation of this idea, double-label immunofluorescence
taining with antibodies to b-galactosidase and alpha SMA
evealed that ephrinB2 was not expressed in the smooth
uscle layer of the dorsal aorta even at E11.5 (Figs. 5A–C),
ut first became detectable in this region at E12.5 (Figs.
D–F), 4 to 5 days after its expression in arterial endothelial
ells can first be detected (Wang et al., 1998; D. Shin and
. J. Anderson, unpublished observations). Strikingly, the
nitial expression of ephrinB2 in arterial smooth muscle
ells occurred in those alpha SMA1 cells closest to the
endothelial layer (Fig. 5F, yellow staining). By E13.5, expres-
sion of ephrinB2 had extended more deeply into the smooth
muscle layer (Fig. 5G). At these embryonic stages, expres-
sion of ephrinB2 in the endothelial layer was stronger than
in the smooth muscle layer. However in adults, the levels of
expression in the two layers were comparable (Fig. 5J and
Fig. 4E).
ephrinB2 Is Expressed in Subsets of Microvessels at
Sites of Adult Neovascularization
We next used ephrinB2taulacZ/1 indicator mice to deter-
ine whether ephrinB2 is expressed in different settings
f adult neovascularization. One model system is the
orneal micropocket assay (Kenyon et al., 1996). Implan-
ation of a pellet of VEGF into a corneal micropocket
aused new ephrinB21 vessels to sprout from the limbus
artery towards the pellet (Figs. 6A– 6C). Double-labeling
using X-Gal and anti-PECAM immunoperoxidase histo-
chemistry indicated that ephrinB2 expression was de-
tected in a subset of the ingrowing vessels and extended
into the smallest diameter capillaries of the microvascu-
lature. (Figs. 6D, E). This was confirmed by double-label
immunofluorescence staining with antibodies to
b-galactosidase and PECAM-1 (Fig. 6H, arrowheads). To
erify that expression of ephrinB2 occurred in newly
ormed rather than preexisting vessels, dividing endothe-
ial cells were labeled in vivo by an injection of BrdU and
he tissue was processed for double-label immunofluores-
ence staining with antibodies to BrdU and
s of reproduction in any form reserved.
144 Shin et al.
(
F
a
(
a
e
E
muscle layer of the adult aorta (J–L). All confocal images were captured using 40X objective.
145Arterial-Specific Expression of EphrinB2 in AdultsFIG. 3. EphrinB2 expression is detected in subsets of microvessels of adult tissues. (A–C) Sections double-labeled by X-Gal histochemistry for
b-galactosidase and anti-PECAM-1 immunoperoxidase histochemistry. (D–O) double-labeled confocal microscopic images with anti-b-gal (red)
and PECAM-1 (green) antibodies. (D–F, J–L) From ephrinB2taulacZ/1 mice, (G–I, M–O) are from EphB4taulacZ/1 mice. The tissues shown are pancreas
A), leg muscle (B, J–O), intestinal fat (C), and kidney glomeruli (D–I). All confocal images were captured using a 40X objective.
IG. 4. EphrinB2 is expressed in smooth muscle cells as well as in endothelial cells of adult arteries. (A–D) X-Gal staining of abdominal
orta (A), thoracic aorta (B), iliac aorta (C), dorsal aorta and vena cava (D). Arrows indicate endothelial cells in the aorta and arrowheads in
D) indicate those in the vena cava. (E, F) Double-label immunohistochemistry of an artery in the kidney. (E) Anti-PECAM-1 (green) vs
nti-b-galactosidase (red) demonstrates ephrinB2 expression in the endothelial layer (yellow). (F) Anti-SMA (green) and anti-b-galactosidaseFIG. 5. Induction of ephrinB2 expression in the smooth muscle layer of embryonic trunk dorsal aorta follows that in the endothelial layer.
Sections were taken from embryos at E11.5 (A–C), E12.5 (D–F), E13.5 (G–I), and Adult (J–L). In all case, the sections are double-labeled with
anti-SMA to visualize smooth muscle cells (green), and anti-b-galactosidase (red) to visualize ephrinB2 expression. Note that ephrinB2 is
xpressed only in endothelial cells and not in the smooth muscle layer at E11.5 (A–C), and is first detected in the smooth muscle layer at
12.5 (F), in the layer immediately adjacent to the endothelial layer. Note also the heterogeneity of ephrinB2 expression in the smooth(red) demonstrate ephrinB2 expression in the smooth muscle layer (yellow).
Copyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
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146 Shin et al.b-galactosidase. This experiment confirmed that eph-
inB21 vessels growing into the cornea indeed contained
rdU1 cells (Fig. 6K, arrowheads) and therefore repre-
sented neovascularization.
We also examined ephrinB2 expression in a more physi-
ological setting of neovascularization, wound healing.
Strong staining in what appeared to be blood vessels was
apparent in wounded tissue undergoing healing (Figs. 7A,
B). This was confirmed by double-labeling with X-Gal
histochemistry and anti-PECAM-1 antibody staining (Figs.
7C, D), which also indicated that ephrinB2 was expressed
by a subset of the small vessels in the wounded region (Fig.
7C, D, arrowheads). Staining was also detected in a subset
of vessels in normal skin, albeit at apparently lower levels
(not shown).
Finally, we addressed the question of whether ephrinB2
is expressed during tumor angiogenesis by implanting
either Lewis Lung carcinoma or B16 Melanoma cells subcu-
taneously into ephrinB2taulacZ/1 indicator mice. After several
eeks, the tumors were sectioned and double-labeled by
-Gal immunohistochemistry and anti-PECAM antibody
taining. In both cases, extensive expression of ephrinB2 was
bserved within the tumor vasculature (Figs. 8A, B). Double
abeling confirmed that the ephrinB21 elements were indeed
ECAM-11 blood vessels (Figs. 8C, D, arrows), and indicated
hat a subset of the PECAM-11 vessels were ephrinB22 in both
umor models (Figs. 8B–D, arrowheads).
DISCUSSION
EphrinB2 and its receptor EphB4 are expressed by devel-
oping arteries and veins, respectively, and are essential for
embryonic heart development and angiogenesis (Adams et
l., 1999; Gerety et al., 1999; Wang et al., 1998). Here we
show that the specific expression of this ligand-receptor
pair in arterial and venous endothelial cells, respectively,
persists into adulthood in most tissues we examined. Sur-
prisingly, ephrinB2 is also expressed in arterial smooth
muscle cells, but this expression is delayed by several days
relative to its onset in the endothelium. In addition to its
steady-state expression in mature vessels, ephrinB2 expres-
sion is also observed in newly forming blood vessels in
several settings of adult angiogenesis.
These findings are significant for several reasons. First,
they indicate that molecular distinctions between arteries
and veins are not simply a transient feature of the develop-
ing circulatory system, but persist into adulthood as well.
Second, they identify a stable genetic difference between
the smooth muscle cells of arteries and veins. Third, they
challenge several traditional concepts about the identity of
vessels in capillary beds and the topography of neovascular-
ization. Finally, given the essential role of ephrinB2 and
EphB4 in embryonic angiogenesis, the data suggest that
these genes may play an important role in neovasculariza-
tion as well.
Copyright © 2001 by Academic Press. All rightMolecular Distinctions between Arteries and Veins
Persist into Adulthood
ephrinB2 is the first gene to be described that is expressed
in an arterial-specific manner from early in embryogenesis
into adulthood, and which is functionally essential for
angiogenesis as well. Recently, the transmembrane receptor
protein tyrosine phosphatase (RPTP) m has been shown to
e expressed in adult arteries but not veins in a variety of
issues (Bianchi et al., 1999). However in contrast to eph-
inB2, RPTPm is expressed in an apparently pan-endothelial
anner in the embryo (Fuchs et al., 1998; Sommer et al.,
996). Furthermore, no functional role for RPTPm in angio-
genesis has yet been demonstrated. Recently, a novel Notch
ligand, Dl14, was shown to be artery-specific in both
embryos and adults (Shutter et al., 2000). A functional
requirement for this gene in angiogenesis has not yet been
directly demonstrated (Krebs et al., 2000).
In addition to the aforementioned cell surface mol-
ecules, several transcription factors have been reported to
be specifically expressed in arterial endothelial cells.
Sox-13, an HMG box factor, is expressed in embryonic
arteries but not veins of midgestational embryos (Roose
et al., 1998). However, unlike ephrinB2 which is ex-
pressed in developing blood vessels as early as E8 –E8.5,
expression of Sox-13 is not detected until E13.5. It is not
yet clear whether the artery-specific expression of Sox-13
is maintained into adulthood. Arterial-specific expres-
sion of EPAS-1, a close relative of the hypoxia-inducible
factor 1a transcription factor (Ema et al., 1997; Flamme
et al., 1997; Tian et al., 1997), has been detected as early
as E11.5 (Tian et al., 1998). Other studies, however, have
reported low-level expression of this gene in the cardinal
veins (Flamme et al., 1997). Whether vessel-specific ex-
pression of EPAS-1 persists into adulthood is not yet
known. Members of a novel family of Hairy-related
bHLH transcription factors, HRT1-3, have also been
shown recently to be expressed specifically in arterial
cells during embryonic development, but whether this
arterial specificity persists into adulthood is not yet clear
(Nakagawa et al., 1999). Interestingly, these genes appear
closely related to the zebrafish gene gridlock, which is
expressed early in arterial development and is required
for proper aorta assembly (Zhong et al., 2000).
It is particularly striking that expression of ephrinB2 and
EphB4 in the adult vasculature extends into the smallest
diameter microvessels and capillaries in a variety of tissues.
This observation suggests that capillaries, as well as larger
diameter vessels, can have arterial and venous identity.
Previous support for this idea derived from enzymatic
histochemical staining of the capillary beds: the arterial
side of the capillary bed expresses alkaline phosphatase,
while the venous side expresses dipeptidylpeptidase IV
(DPPIV) (Koyama et al., 1998; Lojda, 1979; Mra´zkova´ et al.,
1986). Whether these enzymatic differences reflect differ-
ences in gene expression, or differences in activity due to
s of reproduction in any form reserved.
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147Arterial-Specific Expression of EphrinB2 in Adultsposttranscriptional or posttranslational mechanisms, is not
clear. The nature of the transition between the arterial and
venous domains of the capillary bed also remains uncertain.
The above-mentioned histochemical staining technique
demonstrated a “transitional zone” in which both the
arterial and the venous activities overlap (Mra´zkova´ et al.,
1986), but whether this reflects coexpression of both activi-
ties in individual endothelial cells or a zone of intermixing
between cells expressing one or the other marker remains
to be determined. Double labeling for ephrinB2 and EphB4
may help to resolve this issue, once the appropriate reagents
are available.
ephrinB2 Is Expressed Preferentially in Arterial
Vascular Smooth Muscle
An unexpected finding was that ephrinB2 is expressed in
an artery-specific manner in smooth muscle as well as
endothelial cells. The only other documented examples of
such arterial-specific smooth muscle gene expression are
EVEC/DANCE, an EGF-like-repeat-containing secreted
protein (Kowal et al., 1999; Nakamura et al., 1999), and the
“latent TGFb-binding protein-2” (LTBP-2) (Fang et al.,
997). Unlike ephrinB2, however, expression of EVEC/
ANCE is down-regulated after development and is virtu-
lly undetectable in adult arterial smooth muscle, although
t can be reinduced upon injury (Kowal et al., 1999; Naka-
ura et al., 1999). LTBP-2 expression has only been exam-
ned in mid- to late-gestational embryos (Fang et al., 1997),
o it is not clear whether its expression persists into
dulthood, and if so whether its artery specificity is main-
ained. To our knowledge, therefore, ephrinB2 constitutes
he first example of a stable genetic difference between
rterial and venous smooth muscle cells. The existence of
ersistent differences in gene expression between arterial
nd venous smooth muscle cells may underlie the funda-
ental differences observed in the organizational architec-
ure of arteries and veins of comparable internal diameters.
nterestingly, the observation that promoter elements of
he smooth muscle-specific SM22 gene direct expression in
rterial but not venous smooth muscle cells in transgenic
ice (Li et al., 1996) suggests that even genes which are
expressed in all vascular smooth muscle cells may be
controlled by distinct transcriptional regulatory programs
in arteries and veins.
The expression of ephrinB2 in arterial vascular smooth
muscle was missed in initial studies of ephrinB2 expres-
sion in the cardiovascular system (Adams et al., 1999;
Wang et al., 1998), because the analysis was restricted to
embryonic stages before E10.5, and the gene is not
activated in smooth muscle until E12.5. This observation
suggests that distinct mechanisms may control the tim-
ing of onset of ephrinB2 expression in endothelial cells
and vascular smooth muscle cells. Interestingly, the first
detectable expression of ephrinB2 in VSMCs was in the
Copyright © 2001 by Academic Press. All rightlayer immediately adjacent to the endothelium. This
suggests that an inductive signal from arterial ECs to
VSMCs may induce expression of ephrinB2 in the latter
cells. The confirmation of such an inductive process and
the identification of the relevant signal(s) will be inter-
esting topics for future study.
The fact that the onset of ephrinB2 expression in
vascular smooth muscle occurs at E12.5 precludes an
analysis of its functional requirement in this tissue in
ephrinB22/2 embryos, which die by E10.5. The availabil-
ity of conditional knockouts in the ephrinB2 gene should,
in principle, permit a determination of whether its ex-
pression in arterial smooth muscle reflects an essential
function in these support cells as well as in endothelial
cells.
Expression of ephrinB2 in Adult
Neovascularization
ephrinB2 is expressed at sites of adult neovascularization
in at least three different settings: VEGF-induced angiogen-
esis in the cornea, cutaneous wound healing, and tumor
angiogenesis. In each case, the marker is expressed in a
subset of newly forming vessels. This strongly suggests that
such vessels have arterial or venous identity, and that such
identity differences may therefore be important for the
formation of new vascular circuitry. These observations
also challenge prevailing concepts about the topology of
neovascularization. For example, in both corneal neovascu-
larization and tumor angiogenesis, it had been thought that
pairs of new vessels sprout from the postcapillary venule to
form a “bucket-handle”-like structure that shunts blood
out of the venule into the adjacent tissue (Gimbrone et al.,
1974; Grunt et al., 1986). How such loops acquire an
afferent and efferent sidedness was not clear, however. Our
data in the cornea clearly reveal ephrinB21 vessels sprout-
ing toward the VEGF pellet implant (Fig. 6). The presence of
this arterial marker suggests that the traditional classifica-
tion of all new vessel sprouts as being of venous origin,
based purely on morphological criteria, may have been
incorrect. If a subset of neovessels sprouts from arteries and
connect with corresponding sprouts deriving from veins, it
could explain how the “bucket-handle” structure develops
with an intrinsic afferent-efferent polarity. A similar sce-
nario could occur during tumor angiogenesis. More detailed
studies of the topological origin of ephrinB21 vessels in
tumor angiogenesis and their relationship to neovessels
derived from the postcapillary venules should shed further
light on this issue.
The fact that ephrinB2 is expressed at sites of neovas-
cularization, taken together with its essential require-
ment for angiogenesis in the embryo, suggests that this
ligand (and by extension, its receptor(s) (Gerety et al.,
1999)) may be functionally important for adult blood
vessel remodeling as well. In support of this idea, other
s of reproduction in any form reserved.
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in embryonic angiogenesis have also proven essential for
adult neovascularization (reviewed in Yancopoulos et al.,
1998). It is currently not yet possible to examine this in
ephrinB2 knockout mice because of the embryonic le-
FIG. 6. EphrinB2 is expressed during adult neovascularization in
he corneal micropocket assay. (A) Image of live cornea containing
mplanted VEGF pellet, showing blood-filled vessels growing to-
ard the implant. (B, C) X-Gal staining of whole mounted cornea
emonstrates that newly established arterial blood vessels express
phrinB2. (D, E) Double staining for X-Gal and anti-PECAM-1
emonstrates ephrinB2 expression in the region containing newly
ormed blood vessels. (F–H) Double-label confocal immunofluores-
ence microscopy with antibodies to PECAM-1 (F, red) and
b-galactosidase (G, green) directly demonstrates that ephrinB2 is
expressed in a subset of blood vessels (H, arrowheads). (I–K)
Double-labeling with antibodies to BrdU (I, red) and b-galactosidase
(J, green) demonstrates that the ephrinB21 blood vessels are newly
formed (K, arrowheads). The strong band of b-gal expression (E, H,
arrows) represents ephrinB2 expression in epithelial cells and was
not detected in wild-type animals (not shown).thality of the homozygous mutation. However, condi- p
Copyright © 2001 by Academic Press. All rightFIG. 7. Expression of ephrinB2 in a subset of vessels during
cutaneous wound healing. (A, B) X-Gal histochemistry and
hematoxylin staining of wounded cutaneous tissue at low
(A) and high (B) magnification shows ephrinB21 blood vessels in
ealing tissue. Arrow in (A) indicates the wound canal.
C, D) Double labeling with X-Gal histochemistry and anti-
ECAM antibody staining (brown) reveals apparent communi-
ation between ephrinB21 (arrowheads) and ephrinB22 (arrows)
vessels. (D) A higher magnification view of the field shown
in (C).
FIG. 8. Expression of ephrinB2 in a subset of tumor vessels.
Sections through tumors in ephrinB2taulacZ/1 mice implanted with
ewis Lung carcinoma (A, C) or B16 melanoma (B, D) cells were
ouble-labeled with X-Gal (blue) and anti-PECAM immunohis-
ochemistry (brown). (C, D) Higher magnification views of the
elds shown in (A) and (B), respectively. Arrowheads indicate
ECAM1, an ephrinB22 vessels and arrows indicate double-
ositive vessels.
s of reproduction in any form reserved.
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should provide one approach to addressing this question.
If ephrinB2 and its receptor(s) prove to be important in
adult neovascularization, it would suggest that pharma-
cologic manipulation of this ligand-receptor interaction
may provide an alternative route to pro- and anti-
angiogenic therapies for heart disease and cancer, respec-
tively (Folkman, 1998a,b), as has been demonstrated for
other signaling systems important in angiogenesis (Lin et
al., 1998).
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